Published in Semin Intervent Radiol on September 01, 2011
Update on gastric varices. World J Gastrointest Endosc (2014) 0.89
The risk factors for bleeding of fundal varices in patients with liver cirrhosis. Gut Liver (2013) 0.81
Thrombocytopenia in Patients with Gastric Varices and the Effect of Balloon-occluded Retrograde Transvenous Obliteration on the Platelet Count. J Clin Imaging Sci (2014) 0.81
Balloon-occluded retrograde transvenous obliteration of gastric varices: concept, basic techniques, and outcomes. Semin Intervent Radiol (2012) 0.78
A Comprehensive Review of Portosystemic Collaterals in Cirrhosis: Historical Aspects, Anatomy, and Classifications. Int J Hepatol (2016) 0.75
Evaluation of gastrointestinal bleeding: Update of current radiologic strategies. World J Gastrointest Pharmacol Ther (2014) 0.75
Variceal bleeding in cirrhotic patients: risk factors, evolution, treatment. Clujul Med (2013) 0.75
Successful treatment of bleeding gastric varices with splenectomy in a patient with splenic, portal, and mesenteric thromboses. Case Rep Surg (2013) 0.75
Balloon occluded retrograde transvenous obliteration for bleeding gastric varices: Eyes see what the mind knows. Indian J Radiol Imaging (2017) 0.75
Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology (1992) 4.22
Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2005) 3.68
A pathophysiologic, gastroenterologic, and radiologic approach to the management of gastric varices. Gastroenterology (2004) 3.50
Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol (1996) 2.81
A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy (2007) 2.78
Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.69
A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology (2001) 2.64
Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center U.S. analysis. Gastrointest Endosc (2009) 2.63
Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol (2001) 2.43
Endoscopic injection sclerosis in bleeding gastric varices. Gastrointest Endosc (1986) 1.99
Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet (2000) 1.95
Risk factors for hemorrhage from gastric fundal varices. Hepatology (1997) 1.92
A pilot study of 2-octyl cyanoacrylate injection for treatment of gastric fundal varices in humans. Gastrointest Endosc (2004) 1.83
Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology (2006) 1.82
Gastric varices: profile, classification, and management. Am J Gastroenterol (1989) 1.75
The use of thrombin injections in the management of bleeding gastric varices: a single-center experience. Gastrointest Endosc (2008) 1.65
Endoscopic use of human thrombin in bleeding gastric varices. Am J Gastroenterol (2002) 1.65
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology (2006) 1.57
Long-term follow-up of gastric variceal sclerotherapy: an eleven-year experience. Gastrointest Endosc (1997) 1.52
Cost-effectiveness of N-butyl-2-cyanoacrylate (histoacryl) glue injections versus transjugular intrahepatic portosystemic shunt in the management of acute gastric variceal bleeding. Am J Gastroenterol (2003) 1.50
Significance of splenic vein thrombosis in chronic pancreatitis. Am J Surg (2008) 1.38
Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology (2004) 1.38
The natural history of pancreatitis-induced splenic vein thrombosis. Ann Surg (2004) 1.34
N-butyl-2-cyanoacrylate: a supplement to endoscopic sclerotherapy. Endoscopy (1987) 1.31
Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology (2008) 1.26
Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc Intervent Radiol (1997) 1.21
Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant (2007) 1.20
Balloon-occluded retrograde transvenous obliteration of high risk gastric fundal varices. Am J Gastroenterol (1999) 1.19
Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology (1999) 1.13
Clinical implications of the white nipple sign and its role in the diagnosis of esophageal variceal hemorrhage. Am J Gastroenterol (1996) 1.12
The short-term effects of balloon-occluded retrograde transvenous obliteration, for treating gastric variceal bleeding, on portal hypertensive changes: a CT evaluation. Korean J Radiol (2007) 1.11
Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology (2006) 1.11
Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol (2003) 1.11
Enbucrilate for gastric varices: extended experience in 92 patients. Aliment Pharmacol Ther (2007) 1.05
Gastric varices: an updated review of management. J Clin Gastroenterol (2011) 1.03
Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology (2001) 1.01
Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam. J Vasc Interv Radiol (2011) 0.95
The International Normalized Ratio (INR) in the MELD score: problems and solutions. Am J Transplant (2010) 0.95
N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis. Am J Gastroenterol (2003) 0.93
Changes in portal systemic pressure gradient after balloon-occluded retrograde transvenous obliteration of gastric varices and aggravation of esophageal varices. Cardiovasc Intervent Radiol (2009) 0.93
Thrombin is effective in arresting bleeding from gastric variceal hemorrhage. Dig Dis Sci (1999) 0.93
Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology (1989) 0.93
Thrombin--an effective treatment for gastric variceal haemorrhage. Gut (1994) 0.92
Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology (2001) 0.92
Pathology of fundic varices of the stomach and rupture. J Gastroenterol Hepatol (2002) 0.90
Injection sclerotherapy of bleeding oesophageal and gastric varices using a flexible endoscope. Acta Med Scand (1982) 0.90
Development of thrombus in the major systemic and portal veins after balloon-occluded retrograde transvenous obliteration for treating gastric variceal bleeding: its frequency and outcome evaluation with CT. J Vasc Interv Radiol (2008) 0.89
Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost (2004) 0.87
Endoscopic therapy for gastric varices. Clin Liver Dis (2010) 0.86
Natural history of gastric varices. Gastroenterology (1993) 0.79
How to minimize blood loss during liver surgery in patients with cirrhosis. HPB (Oxford) (2009) 0.79
Treating gastrointestinal bleeding with endoscopic hemoclips. Surg Laparosc Endosc (1997) 0.79
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Liver biopsy. Hepatology (2009) 7.61
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol (2012) 2.89
Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center U.S. analysis. Gastrointest Endosc (2009) 2.63
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis (2009) 2.22
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol (2009) 2.06
Bleeding and thrombosis in cirrhotic patients: what really matters? Dig Liver Dis (2011) 1.54
Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? J Clin Gastroenterol (2009) 1.47
Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int (2013) 1.47
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int (2011) 1.46
Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis. Hepatology (2005) 1.39
Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol (2006) 1.27
Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci (2014) 1.27
Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol (2013) 1.24
Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J Atheroscler Thromb (2009) 1.02
Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res (2008) 1.02
The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology (2004) 1.00
A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol (2008) 0.98
Statins in liver disease: a molehill, an iceberg, or neither? Hepatology (2008) 0.96
Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl (2003) 0.95
Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam. J Vasc Interv Radiol (2011) 0.95
Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol (2006) 0.93
N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis. Am J Gastroenterol (2003) 0.93
A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol (2012) 0.91
Treatment of hepatitis C virus infection. Ann Intern Med (2015) 0.91
Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med (2015) 0.89
Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities. Technol Cancer Res Treat (2009) 0.88
The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue? Clin Liver Dis (2009) 0.88
Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list. Transpl Int (2013) 0.87
Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma? Gastrointest Cancer Res (2012) 0.85
Enlarged hepatocytes in NAFLD examined with osmium fixation: does microsteatosis underlie cellular ballooning in NASH? Am J Gastroenterol (2006) 0.84
Pre- and post-balloon-occluded retrograde transvenous obliteration clinical evaluation, management, and imaging: indications, management protocols, and follow-up. Tech Vasc Interv Radiol (2012) 0.83
Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Preprocedural Evaluation and Imaging. Semin Intervent Radiol (2011) 0.83
The role of recombinant factor VIIa in liver transplantation. Liver Transpl (2005) 0.82
Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis (2012) 0.80
Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related? Dig Dis Sci (2006) 0.80
Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet. Liver Int (2007) 0.79
Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology (2014) 0.78
Effects of restoring portal flow with anticoagulation and partial splenorenal shunt embolization. Hepatology (2014) 0.76
New concepts of coagulation and bleeding in liver disease. Intern Emerg Med (2010) 0.76
Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology (2014) 0.76
Treatment of bleeding gastric varices. J Gastroenterol Hepatol (2005) 0.75
Propensity for non-alcoholic fatty liver disease: more evidence for ethnic susceptibility. Liver Int (2009) 0.75
Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis. Hepatology (2007) 0.75
How useful is epsilon-aminocaproic acid for the treatment of hyperfibrinolysis in patients with cirrhosis? Nat Clin Pract Gastroenterol Hepatol (2006) 0.75
Liver invasion of the duodenum due to hepatocellular carcinoma. Clin Gastroenterol Hepatol (2012) 0.75
The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit. Pharmacoepidemiol Drug Saf (2003) 0.75
Nonalcoholic fatty liver disease, portal vein thrombosis and coagulation: more questions than answers? Transplantation (2017) 0.75
Creation of a transjugular intrahepatic portosystemic shunt with use of a preexisting portal-hepatic vein fistula as an alternative route. J Vasc Interv Radiol (2005) 0.75